Is Trastuzumab injection (subcutaneous injection) (Herceptin Hylecta) included in medical insurance?

Trastuzumab injection (subcutaneous ) (Herceptin Hylecta) is approved for the treatment of adult patients with HER2-positive breast cancer (HER2+). Trastuzumab injection (subcutaneous injection) is a fixed treatment combination containing trastuzumab and hyaluronidase. It is a colorless to slightly yellow, clear to milky white subcutaneous injection solution that is administered by subcutaneous injection. This form can be administered by infusion over a shorter period of time than trastuzumab. Do not use trastuzumab injection (subcutaneous injection) instead of ado-trastuzumab emtansineado-trastuzumab emtansine.

The treatment of trastuzumab injection (subcutaneous injection) must be for hormone receptor negative or high-risk breast cancer. It can be combined with other drugs for chemotherapy, such as doxorubicin, cyclophosphamide and paclitaxel or docetaxel chemotherapy combination or docetaxel and carboplatin; after single drug treatment, anthracycline chemotherapy can be selected. Trastuzumab injection (subcutaneous injection) is also used to treat metastatic breast cancer, where it can be used in combination with paclitaxel as a first-line treatment of cancer, or it can be used alone in patients who have already received at least one chemotherapy regimen for metastatic disease.

It is understood that the original drug of trastuzumab injection (subcutaneous injection) has been launched in China, but the specific price and other relevant information are not yet clear. Because the drug has been on the market for a short time, it has not been included in the scope of medical insurance through the relevant regulations of the National Medical Insurance Administration. At present, there are no generic drugs of Trastuzumab injection (subcutaneous injection) produced and marketed. For more information and specific prices of Trastuzumab injection (subcutaneous injection), please consult a medical consultant.